Monday 23 April |
Foreign & Colonial Investment Trust |
Bioquell |
Microgen |
HgCapital Trust |
Silence Therapeutics |
Tuesday 24 April |
Shire |
Hammerson |
Metro Bank |
London Stock Exchange Group |
Tribal Group |
Alfa Financial Software Holdings |
UK Oil & Gas Investments |
Wednesday 25 April |
Drax Group |
British American Tobacco |
CLS Holdings |
Croda International |
Devro |
Mithras Investment Trust |
Nichols |
Personal Group Holdings |
Polar Capital Global Financials Trust |
Tullow Oil |
Countrywide |
EP Global Opportunities Trust |
Persimmon |
intu properties |
BlackRock World Mining Trust |
Polymetal International |
Thursday 26 April |
CRH |
Sthree |
Elementis |
Murray International Trust |
STV Group |
Admiral Group |
Fidessa Group |
French Connection Group |
Just Eat |
Aggreko |
Cobham |
FDM Group |
LSL Property Services |
Meggitt |
RIT Capital Partners |
Schroders |
SDL |
Synthomer |
Taylor Wimpey |
Weir Group |
Friday 27 April |
Rotork |
Ultra Electronics Holdings |
Travis Perkins |
Merlin Entertainments |
LMS Capital |
Laird |
Hutchison China Meditech |
Senior |
IN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan Eldar
Hutchmed (China) Ltd - Hong Kong-headquartered biopharmaceutical company - Chair Simon To retires from his role as chair, succeeded by Dan Eldar, effective immediately. Former chair To agrees to serve as strategic advisor to Hutchmed and will continue to contribute to the company "on significant matters". In a separate release, the company highlights Sovleplenib phase 3 data in adult patients with primary immune thrombocytopenia who have received at least one prior line of standard therapy. ITP is an autoimmune disease characterised by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Hutchmed will present the data in mid-June in Madrid.
Read more